Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger [Yahoo! Finance]
NLS Pharmaceutics Ltd. - Ordinary Shares (NLSP)
Company Research
Source: Yahoo! Finance
ZURICH and NESS ZIONA, Israel Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage cell therapy company progressing treatments for neurodegenerative diseases and diabetes, today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective the registration statement on Form F-4 related to the companies' previously announced merger. The Form F-4 became effective on September 9, 2025 , at 4:00 p.m. Eastern Time Ronen Twito, Kadimastem's Executive Chairman and CEO and Alexander C. Zwyer NLS's CEO & Executive Board Member stated: SEC effectiveness marks a major milestone in the planned merger of NLS and Kadimastem to form NewCelX Ltd. This marks the final U.S. federal securities regulatory hurdle required for closing the merger. Upon com
Show less
Read more
Impact Snapshot
Event Time:
NLSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLSP alerts
High impacting NLS Pharmaceutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NLSP
News
- NLS Pharmaceutics (NASDAQ:NLSP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NLSP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger [Yahoo! Finance]Yahoo! Finance
- NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of MergerPR Newswire
- NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon LabsPR Newswire
- NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following MergerPR Newswire
NLSP
Sec Filings
- 11/13/25 - Form SCHEDULE
- 11/3/25 - Form 6-K
- 10/30/25 - Form 25-NSE/A
- NLSP's page on the SEC website